This goal of this project is to develop an innovative process for treating patients with Waldenstr?m's macroglobulinemia by suppressing the production of IgM. Waldenstr?m's macroglobulinemia is incurable and fatal. The manifestations of this disease that are due to high concentrations of monoclonal IgM are hyperviscosity with headache, fatigue, impaired cognition, confusion, and stroke, peripheral neuropathy and systemic amyloidosis which may result in death. We hypothesize that the production of IgM by malignant plasma cells can be stopped by using RNA interference which can be administered systemically and specifically targets the plasma cells which produce IgM. This will be accomplished by using an innovative recombinant fusion protein that targets the malignant plasma cells by its antigen binding portion and delivers the RNA interference into the plasma cells by natural internalization. The fusion protein consists of an antibody fragment for cell specific targeting and a modified version of human protamine for carrying the short interfering RNA to the tissue and into the plasma cells. This treatment will be tested in a mouse model of Waldenstr?m's macroglobulinemia.
Our Specific Aims are 1. Create fusion proteins that maintain cell binding, are internalized by the malignant plasma cells and then inhibit IgM production;2. Optimize the functional behavior of the fusion proteins;3. Demonstrate the in vivo anti- malignant behavior of the fusion proteins. Our method will overcome the major impediment to the use of RNA interference systemically, i.e. inability of present methods to deliver RNA interference by systemic administration with specific targeted cellular and tissue delivery. Our Phase II objectives will include optimization of dosage and assessment of side effects using an animal model of this disease.

Public Health Relevance

There is an unmet and urgent need for new therapeutic approaches to treat Waldenstr?m's macroglobulinemia; a disease which leads to disability and then death. This treatment will also be directly applicable to treating other diseases which involve the production of abnormal antibodies by antibody producing cells (plasma cells). The therapy consists of a synthetic protein which is part antibody which homes the molecule to its target (plasma cells). The other part of the synthetic molecule binds interfering RNA which is delivered into the targeted cells. The interfering RNA then turns off the production of the IgM macroglobulin that causes many of the disease manifestations of macroglobulinemia.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-OTC-H (13))
Program Officer
Lou, Xing-Jian
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sirnax, Inc.
Ann Arbor
United States
Zip Code